ARTICLE | Product Development
Also in BioCentury’s Clinical Report: ASH readouts from Cardiff Oncology, Arcellx and GSK; plus data from NewAmsterdam, AbbVie and more
By Lauren Martz, Executive Director of Biopharma Intelligence, and Paul Bonanos, Director of Biopharma Intelligence
December 11, 2024 12:10 AM UTC
The latest data on zilovertamab vedotin from Merck & Co. Inc. (NYSE:MRK) suggest the pharma may have found the next antibody-drug conjugate (ADC) with the right combination of payload, linker and target to achieve clinical success.
At the American Society of Hematology (ASH) meeting, Merck reported that a 1.75 mg/kg dose of the ROR1-targeting ADC — the most advanced in its class — plus R-CHP chemotherapy led to a 100% complete response rate in 15 previously untreated patients with diffuse large B-cell lymphoma (DLBCL) in the Phase II waveLINE-007 study. An additional 14 patients were treated at 2.0 mg/kg and six at 2.25 mg/kg, where the complete response rates were 93.3% and 97.2%, respectively. The findings promise a step up from the 60-70% complete response rate typically seen with first-line standard of care…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654433/ror1-shines-as-the-next-promising-adc-target